155 related articles for article (PubMed ID: 15218309)
1. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Agelaki S; Syrigos K; Christophylakis C; Boukovinas J; Varthalitis J; Pavlakou G; Athanasiadis A; Kouroussis C; Vardakis N; Maltezakis G; Milaki G; Georgoulias V;
Oncology; 2004; 66(3):192-6. PubMed ID: 15218309
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
Ohyanagi F; Horiike A; Okano Y; Satoh Y; Okumura S; Ishikawa Y; Nakagawa K; Horai T; Nishio M
Cancer Chemother Pharmacol; 2008 Mar; 61(3):503-8. PubMed ID: 17483949
[TBL] [Abstract][Full Text] [Related]
4. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study.
Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C
Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Rocha-Lima CM; Herndon JE; Lee ME; Atkins JN; Mauer A; Vokes E; Green MR;
Ann Oncol; 2007 Feb; 18(2):331-7. PubMed ID: 17065590
[TBL] [Abstract][Full Text] [Related]
7. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Georgoulias V; Kouroussis C; Agelidou A; Boukovinas I; Palamidas P; Stavrinidis E; Polyzos A; Syrigos K; Veslemes M; Toubis M; Ardavanis A; Tselepatiotis E; Vlachonikolis I;
Br J Cancer; 2004 Aug; 91(3):482-8. PubMed ID: 15238986
[TBL] [Abstract][Full Text] [Related]
8. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS; Khuri FR; Lu C; Liu DD; Fossella FV; Glisson BS; Pisters KM; Shin DM; Papadimitrakopoulou VA; Kurie JM; Blumenschein G; Kies MS; Zinner R; Jung MS; Lu R; Lee JJ; Munden RF; Hong WK; Lee JS
Cancer; 2002 Jul; 95(2):340-53. PubMed ID: 12124835
[TBL] [Abstract][Full Text] [Related]
9. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M
Jpn J Clin Oncol; 2006 Sep; 36(9):547-51. PubMed ID: 16870693
[TBL] [Abstract][Full Text] [Related]
11. Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Rocha Lima CM; Eckardt JR; Leong SS; Sherman CA; Perkel JA; Putman T; Safa AR; Bahadori HR; Green MR
Semin Oncol; 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2. PubMed ID: 10585008
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Akerley W; McCoy J; Hesketh PJ; Goodwin JW; Bearden JD; Atkins JN; Chansky K; Crowley JJ; Gandara DR;
J Thorac Oncol; 2007 Jun; 2(6):526-30. PubMed ID: 17545848
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
17. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Stathopoulos GP; Rigatos SK; Dimopoulos MA; Giannakakis T; Foutzilas G; Kouroussis C; Janninis D; Aravantinos G; Androulakis N; Agelaki S; Stathopoulos JG; Georgoulias V;
Ann Oncol; 2003 Mar; 14(3):388-94. PubMed ID: 12598343
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Rocha Lima CM; Savarese D; Bruckner H; Dudek A; Eckardt J; Hainsworth J; Yunus F; Lester E; Miller W; Saville W; Elfring GL; Locker PK; Compton LD; Miller LL; Green MR
J Clin Oncol; 2002 Mar; 20(5):1182-91. PubMed ID: 11870159
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Chaudhary UB; Verma N; Keane T; Gudena V
Am J Clin Oncol; 2014 Apr; 37(2):188-93. PubMed ID: 23241501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
